Author

Andrew Paul

University of StrathclydeORCID 0000-0001-5775-2332Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Assay:proteomics· 1

Frequent Co-Authors

Simon Paul MackayiD· 2 shared Andrew Michael FreyiD· 1 shared Anke HusmanniD· 1 shared Anthony J. ChalmersiD· 1 shared Chao Zheng Li· 1 shared Christopher J. LordiD· 1 shared Christopher P. A. T. LawsoniD· 1 shared David R. AdamsiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Simon Paul MackayORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintApr 23, 2026

ClonoScreen3D-CRISPRi Uncovers Genetic Modifiers of Radiation Response in Glioblastoma

Sukjun Lee, Anke Husmann, Jianbin Li…·Erica Bello

This study introduces ClonoScreen3D-CRISPRi, a 3D clonogenic survival assay combined with CRISPRi, to identify genetic modifiers of radioresistance in GBM, finding NFKB2, RELB, and CDK9 as potent radiosensitizers.

DOI 10.64898/2026.04.17.719014

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJan 31, 2025

Targeting non-canonical NF-κB signalling in CYLD cutaneous syndrome by selective inhibition of IκB kinase alpha.

Kirsty Hodgson, Joseph Inns, Gary Reynolds…·Neil Rajan

This study identifies non-canonical NF-κB signalling as a therapeutic target in CYLD cutaneous syndrome and shows that IKK inhibition reduces tumor viability in patient-derived models.

3 citations

humanproteomics

𝕏 PostBluesky